Dogwood (DWTX) Therapeutics enrolled the first 100 patients in its ongoing HALT-CINP Phase 2b CINP trial. HALT-CINP remains on track to conduct a prespecified interim analysis during the fourth quarter of 2025 on patients who have completed or been terminated from the four-week study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DWTX:
- Strategic Acquisitions and Promising Trials Bolster Buy Rating for Dogwood Therapeutics
- Dogwood Therapeutics Advances Pain Treatment Pipeline
- Dogwood reports Q3 EPS ($8.20) vs ($2.05) last year
- Dogwood Therapeutics Announces Business Combination Plans
- Dogwood to present on Halneuron pain research program